Science Breaktroughs The Koyal Group InfoMag News: Japanese stem-cell ‘breakthrough’ findings retracted

Research into one of the biggest recent stem-cell “breakthroughs" has been withdrawn because of "critical errors".

Scientists in Japan had claimed stem cells could be made cheaply, quickly and ethically just by dipping blood cells into acid.

They have now written a retraction that apologises for “multiple errors” in their report.

Nature, the journal that published the findings, is reviewing how it checks scientific papers.

Stem cells can become any other type of tissue and are already being investigated to heal the damage caused by a heart attack and to restore sight to the blind.

Researchers around the world described the acid-bath stem-cell finds as a “game changer,” “remarkable” and “a major scientific discovery”.

Falling apart

However, errors were rapidly discovered, parts were lifted from early work and presented as though it was new research, and leading scientists have been unable to produce stem cells using acid in their own laboratories.

An investigation by the Riken research institute in Japan found that scientist Dr Haruko Obokata had fabricated her work in an intentionally misleading fashion.

The retraction states: “These multiple errors impair the credibility of the study as a whole and we are unable to say without doubt whether the stimulus-triggered acquisition of pluri­potency stem cells phenomenon is real.

Ongoing studies are investigating this phenomenon afresh, but given the extensive nature of the errors currently found we consider it appropriate to retract both papers.”

The affair brings back memories of the false claims by world-renowned cloning scientists Hwang Woo-suk.

He claimed he had produced embryonic stem cells from cloned human embryos, but those findings were later found to be “intentionally fabricated”.

'Highlighted flaws'

A Nature editorial stated that the public’s trust in science was at stake in the latest controversy.

It added: “Although editors and referees could not have detected the fatal faults in this work, the episode has further highlighted flaws in Nature’s procedures and in the procedures of institutions that publish with us.”

However, it did say a review was under way to increase checking on images used in papers.

The acid-bath stem cells research has not been completely discredited and research is continuing to see if stem cells can be produced using the method.

Chris Mason, a professor of regenerative medicine at University College London, originally said the results were “a very exciting, but surprise, finding” and added: “It looks a bit too good to be true.”

After the retraction, he told the BBC: “I’m surprised that Nature took so long when there was so much material showing problems with the papers. I don’t understand that.”

However, he said the system of peer review, in which fellow scientists critique papers before they are published, would struggle to pick up the problems in this research.

He said: “If you’re a reviewer you can only review the material you’re given. You have to take it on trust. You’re not a detective looking for fraud.

'Good day for science'

"If you have to act as a super-sleuth, that’s impossible for anyone to ever do."

He praised the way social media had uncovered and shared the errors, which could have otherwise taken years to unpick.

"I would argue this is not an embarrassing day for science, I think it’s a good day for science and it shows we work well to weed out inferior publications."

Dr Dusko Ilic, a senior lecturer in stem-cell science at King’s College London, said: “It is easy to be judgmental, and pointing fingers after all is over.

"Gaining knowledge is difficult. It requires both time and persistence, I hoped that Haruko Obokata would prove at the end all those naysayers wrong.

"Unfortunately, she did not. The technology, indeed, sounded too good to be true, though I still find fascinating how a 30-year-old scientist could pass scrutiny of her co-workers and multiple reviewers in Nature with a complete fabrication."

The UK Medical Research Council’s Prof Robin Lovell-Badge added: “The stem cell community has been expecting these retractions to come for a while.

"This story illustrates how the stem cell field can rapidly detect bad science and reject it.

"It also illustrates both the problems and benefits of hype, this was potentially important research because of the novelty of the claims in an important field, but it was hyped far beyond reality, by some of the authors and by their perhaps willing victims, the media."

Science Breakthroughs The Koyal Group InfoMag News: Discovery Science Powered, Increasingly, by Donors

As co-director of the Harvard Stem Cell Institute, David Scadden hopes to inspire his students to join the ranks of researchers who might one day cure Parkinson’s or Alzheimer’s or diabetes. But all too often these days, he is losing out to Wall Street, or other higher-paying pursuits.

“They are seeing their senior mentors spending more and more time writing grants and going hat in hand,” Scadden said, in a phone interview. “That’s not a good way to inspire the best and brightest.”

It is an empirical fact that there’s now far less money going toward research science than there used to be, due first and foremost to the decrease in government spending on such research. The budget of the National Institutes of Health is lower (in inflation-adjusted dollars) that at any point since 2000, and 22 percent lower than it was in 2003.

This has meant that the former star students who chose to spend their lives in a lab, working with stem cells or sequencing genomes, the kind of work that most experts believe will usher in the next great medical revolution, are more reliant than ever on a handful of Americans to fund basic research.

That source of funding, while vital, is unstable and relatively scarce.

“We’re going to lose a generation of young scientists, and that’s not something you can make up,” said Dr. Laurie Glimcher, Dean of Weill Cornell Medical College.

Traditionally, researchers rely on a three-legged stool for funding.

While one leg is made up of government grants, another is made up of industry, which pays scientists to research treatments that can be the next billion-dollar idea. But when it comes to discovery science, whose outcomes are inherently unpredictable and which is often conducted without targeting a specific disease, industry tends to be risk-averse.

That leaves philanthropy.

Fiona Murray, a professor of entrepreneurship at M.I.T., published a paper in 2012 finding that philanthropy, both private and corporate, provides almost 30 percent of the annual research funds for leading universities. She also found that while federal funds have been declining, philanthropic funds have been increasing.

“The role of science philanthropy—gifts from wealthy individuals, grants from private foundations to scientific research, and endowment income earmarked for research—is an underappreciated aspect of philanthropy in higher education whose importance becomes clear by examining trends in funding university research,” Murray wrote. “Industry contributions (usually regarded as the alternative funding stream for university research) amount to less than 6 percent of university research funding. In striking contrast, science philanthropy makes up almost 30 percent of university research funding and has been growing at almost 5 percent annually.”

It’s that funding that has made possible a series of breakthroughs that could have outsize clinical implications during the next few decades.

On the west side of harlem, in an unadorned building, some of the most exciting research in medicine is taking place, and almost all of it is being paid for by private donors.

The New York Stem Cell Foundation is supported in part through the Druckenmiller Foundation. The stem cell foundation’s fellowship program is the largest dedicated stem cell fellowship program in the world, and they are one of the only two labs in the country working successfully on a procedure known somatic cell nuclear transfer.

Remember Dolly the sheep? It’s that kind of science, but a bit further along, and instead of cloning mammals, scientists work to create cells, organs or tissues that can replace diseased cells in the human body.

The federal government, for political and ethical reasons, won’t fund any of it.

Though President Obama reversed the Bush administration’s position on funding stem cell research, no new embryonic stem cell lines can be supported because of something called the Dickey-Wicker Amendment, which is renewed every year and prohibits federal funding for synthesizing new stem cell lines. (The Obama administration allows N.I.H. funding for research on new lines that were created with private dollars.)

“It’s really an illusion that the government has both feet in,” said Susan Solomon, C.E.O. of New York’s Stem Cell Foundation. “Without philanthropy we would not have a single stem cell research program in this country.”

This past April, a team of scientists from the foundation created the first disease-specific embryonic stem cell line with two sets of chromosomes.

That means researchers were able to create patient-specific stem cells from an adult human with type 1 diabetes that can give rise to the cells lost in the disease, according to Dr. Dieter Egli, who led the research and conducted many of the experiments.

The stem cell experiments began at Harvard and the skin biopsies were done at Columbia. But isolation of the cell nuclei from these skin biopsies couldn’t be conducted in the federally funded laboratories at Columbia, and Harvard scientists had to stop research in 2008 because restrictions in Massachusetts prevented them from obtaining human eggs for research.

Stem cell science is one of the most conspicuous areas of research in which philanthropy is being asked to pick up the slack left by receding public investment. And in the specific case of stem cell research, donors have stepped in to make up the lack of public money.

But overall, money for research is way down, reflecting a general aversion by both the public and private sectors to fund medical-science projects without likely short-term rewards.

“As resources have shrunk, the ability to tolerate risk on bold ideas of course decreases,” Scadden said. “There is an increased attention to ‘what’s the payoff, what’s the return on investment? Can you show me a direct link to the way my constituents benefit?’”

The problem is that science, generally speaking, doesn’t work like that. Telomeres, the tips of chromosomes that protect DNA during cell replication, were discovered in the 1930s. No one knew what they did or if they were of practical importance. Today, scientists think they might hold the key to battling tumor development.

“Today’s medical miracles are yesterday’s wild ideas in a basic laboratory,” Scadden said.

Donations to stem cell work aren’t much different in that respect from the $12.5 million donation by former Microsoft C.T.O. Nathan Myhrvold for a telescope that will search for extraterrestrial life. Scientists haven’t found any yet, and may never, but that shouldn’t be the point.

“While it’s impossible to predict exactly what we will find with a new scientific instrument, we should remember that interesting science is not just about the likelihood of end results—it is also about the serendipity that occurs along the way,” Myhrvold said in 2000 when donating the money.

Last year, the American Association for the Advancement of Science began a coalition of funders that aims to double philanthropic support for basic science over the next five years.

“The concern of this group is that there is such a big push on the translation science at the expense of the discovery science, which is essentially feed-corn,” said Vicki Chandler, chief program officer for science at the Gordon and Betty Moore Foundation in California, one of several foundations that joined the coalition. “And if we keep heading [toward] that balance there may not be as many as great things to translate from in the next decade.”

Despite the changing proportions of money for research, the United States government remains the principal lifeline for science. The N.I.H. budget is just under $30 billion, much of which is invested in research grants. Private funding for basic research, the kind that doesn’t attach itself to a specific disease or therapy—is only somewhere between $2 and $4 billion.

The question is how far or fast the balance between public and private funding is shifting, and where it will end.

The more it shifts, the more research scientists are coming to rely on a select few donors, who can drive the agenda.

T. Denny Sanford, for example, donated $100 million last year to the creation of the Sanford Stem Cell Clinical Center at the University of California, San Diego.

“I believe we’re on the cusp of turning years of hard-earned knowledge into actual treatments for real people in need,” Sanford said last November. “I want this gift to push that reality faster and farther.”

In 2012, Mort Zuckerman pledged $200 million for the Mortimer B. Zuckerman Mind Brain Behavior Institute at Columbia University.

The Ansary Stem Cell Institute at Weill Cornell exists because of $15 million donation from Shahla and Hushang Ansary, the major Republican donor and former Iranian diplomat.

But Murray, the M.I.T. professor, found these examples are more exception than rule. Her research found “little support” for the notion that philanthropists fill gaps left by federal funding.

“In addition,” she wrote, “few philanthropists appear to seek to identify such gaps. This fact is underscored by one key fact about philanthropy: philanthropists are more concentrated in their giving to specific (translational) fields than the government, suggesting that with few exceptions … patrons add support to already well-funded wealthy fields instead of filling gaps.”

That’s frustrating, Glimcher said, because scientific research seems so close to potentially important breakthroughs on so many medically significant fronts.

Given new tools for genetic sequencing and a better understanding of chemistry, basic discoveries can yield clinical trials faster than ever before. But not if that basic science isn’t funded.

“It’s frustrating right now because we are at a time when we can translate basic discoveries into new therapies for patients,” Glimcher said. “Philanthropic research can be a temporary stop-gap and a wonderful addition to reduce the sting of cuts in government funding, and it can top off government funding, but it’s never going to replace government.”

Visit Koyal Group InfoMag for more related articles.

The Koyal Group InfoMag News: NASA prepares to capture asteroid, drag it into Earth’s orbit

NASA prepares to a drag an asteroid into Earth’s orbit.

What is the goal for the Asteroid Redirect Mission?

Through the Asteroid Redirect Mission, NASA will identify, capture and redirect an asteroid to a stable orbit around the moon, which astronauts will explore in the 2020s, returning with samples. The mission is an important early step as we learn to be more independent of Earth for humans to explore Mars. It will be an unprecedented technological feat that will lead to new scientific discoveries and technological capabilities, while helping us learn to protect our home planet. The overall objectives of the Asteroid Redirect Mission are:

• Conduct a human exploration mission to an asteroid in the mid-2020s, providing systems and operational experience required for human exploration of Mars.

• Demonstrate an advanced solar electric propulsion system, enabling future deep-space human and robotic exploration with applicability to the nation’s public and private sector space needs.

• Enhance detection, tracking and characterization of Near Earth Asteroids, enabling an overall strategy to defend our home planet.

• Demonstrate basic planetary defense techniques that will inform impact threat mitigation strategies to defend our home planet.

• Pursue a target of opportunity that benefits scientific and partnership interests, expanding our knowledge of small celestial bodies and enabling the mining of asteroid resources for commercial and exploration needs.

What are the requirements for the asteroid NASA hopes to capture?

NASA is working on two concepts for the mission: the first is to fully capture a very small asteroid in open space, and the second is to collect a boulder-sized sample off of a much larger asteroid. Both concepts would require redirecting an asteroid mass less than 32 feet (10 meters) in size into the moon’s orbit.

NASA’s search for candidate asteroids for ARM is a component of the agency’s existing efforts to identify all Near-Earth Objects (NEOs) that could pose a threat to the Earth. More than 11,140 NEOs have been discovered as of June 9. Approximately 1,483 of those have been classified as potentially hazardous. Some of these NEOs become potential candidates for ARM because they are in orbits very similar to Earth’s and come very close to the Earth-Moon system in the early 2020s, which is required to be able to redirect the asteroid mass to be captured into lunar orbit.

To date, nine asteroids have been identified as potential candidates for the ARM full capture option, having favorable orbits and estimated to be within the right size range. Sizes have been established for three of the nine candidates. Another asteroid — 2008 HU4 — will pass close enough to Earth in 2016 for interplanetary radar to determine some of its characteristics, such as size, shape and rotation. The other five will not get close enough to be observed again before the final mission selection, but NASA’s NEO Program is finding a few additional potential candidate asteroids every year. One or two of these get close enough to Earth each year to be well characterized.

Boulders have been directly imaged on all larger asteroids visited by spacecraft so far, such as Itokawa by the Japanese Hayabusa mission, making retrieval of a large boulder a viable concept for ARM. During the next few years, NASA expects to add several candidates for this option, including asteroid Bennu, which will be imaged up close by the agency’s Origins-Spectral Interpretation-Resource Identification-Security-Regolith Explorer (OSIRIS-REx) mission in 2018. High resolution interplanetary radar is also able to image the surfaces of asteroids that pass close to the Earth and infer the presence of large boulders.

Where will the asteroid be redirected to – reports suggest above the Moon?

After an asteroid mass is captured, the spacecraft will redirect it to a stable orbit around the moon called a “Lunar Distant Retrograde Orbit.” Astronauts aboard an Orion spacecraft, launched from a Space Launch System (SLS) rocket, will explore the asteroid there in the mid-2020s. Learning to maneuver large objects utilizing the gravity fields of the Earth and moon will be valuable capabilities for future activities. Potentially, either mission concept might test technology and techniques that can be applied to planetary defense if needed in the future.

How will ARM fit NASA’s goal to visit Mars?

The mission provides experience in human spaceflight beyond low-Earth orbit, building on our experiences on the International Space Station, and testing new systems and capabilities in the proving ground of cis-lunar space, toward the ultimate goal of a crewed mission to Mars. ARM leverages and integrates existing programs in NASA’s Science, Space Technology, and Human Explorations and Operations to provide an affordable – and compelling — opportunity to exercise our emerging deep space exploration capabilities on the path to Mars. ARM will test the transport of large objects using advanced high power, long life solar electric propulsion; automated rendezvous and docking; deep space navigation; integrated robotic and crewed vehicle stack operations in deep space environment; and spacewalks out of Orion that will be needed for future cis-lunar space and Mars missions.

NASA’s strategy is that the ARM SEP module and spacecraft bus would be upgradable for the first cargo missions to Mars and its moons. We might do so by procuring these systems commercially to lower cost and for reproducibility. Another option is to repurpose the ARM vehicle after its first mission, as a lowest cost option for transportation. These are among the options being studied this year.